Atara Biotherapeutics, Inc. (ATRA)
ATRANASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$8.18
+0.3100 (+3.94%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $82.11m
- P/E
- –
- EPS, last 4 quarters
- $-1.18
- Dividend yield
- –
- Day range
- –
- 52-week range
- $3.92 to $19.15
- Average volume
- 36.4k
- Previous close
- $7.87
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $15.50, +89.5% from here
Earnings
Next report Nov 11, 2026
Sep 2025
+61.5%
Dec 2025
-177.8%
Mar 2026
–
Jun 2026
–
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $3.45m | $1.59m | $516.0k | $630.0k |
| Gross profit | $3.34m | $1.49m | $392.0k | $439.0k |
| Operating income | -$3.57m | -$2.56m | -$3.37m | -$4.72m |
| Net income | -$4.30m | -$3.41m | -$4.14m | -$4.83m |
Last four quarters: revenue $6.19m, margin -269.4%, free cash flow –
News
8 latest- Biotech Stocks Move Higher - NIVF +25%, ICU +23%, ATRA +11%, INDP +9% RTTNews · Oct 2, 2026
- Atara Resubmits Tabelecleucel BLA To FDA RTTNews · Sep 30, 2026
- 5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara RTTNews · Sep 8, 2026
- Tuesday 9/8 Insider Buying Report: UBER, ATRA BNK Invest · Sep 8, 2026
- ISpecimen In Focus, Genelux Nears Phase 3 Ovarian Cancer Data, Biofrontera Awaits FDA Decision RTTNews · Sep 8, 2026
- Tenaya Therapeutics Names Eric Hyllengren CFO Ahead Of Higa Retirement RTTNews · Jun 30, 2026
- Atara Announces Departure Of Carol Gallagher As Director, Brian Cherry To Succeed RTTNews · Jun 15, 2026
- ATRA Stock Shoots Up 82% in a Month: Here's What You Should KnowZacks · May 21, 2026
The company
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- atarabio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.